An intravenous, next-generation proteasome inhibitor for third-line treatment of multiple myeloma.
If you have a Hayes login, click here to view the full report on the Knowledge Center.
Complete this form to request the full report.
Hayes Report Sale Policy: Hayes will review your request to purchase a report and respond to you. Individuals requesting reports due to a payment denial should contact the involved health insurer for details and information.
Please contact us if you are interested in a Hayes subscription.